Research

Cellular

Mechanistic studies may explain the cardiovascular benefits of SGLT2 inhibition in T2DM patients.

Practitioners should consider the underlying mechanisms when evaluating the cardiovascular benefits of SGLT2 inhibitors.

GoodQualifiesmedium confidence
We also review the mechanistic studies that might explain the CV benefits of SGLT2 inhibition in patients with T2DM.
Rinkoo Dalan · Cardiology in Review · 2018

Why this rating

The claim is based on a review of mechanistic studies, which are generally less robust than large-scale trials.

Source

Sodium–Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus

Rinkoo Dalan · Cardiology in Review · 2018

DOI 10.1097/crd.0000000000000201

reviewCited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →